Fellowship – EORTC
Fellowship
Fellowship
Researchers sought to determine whether venetoclax plus a hypomethylating agent would be safe and effective in very elderly patients with AML.
Arndt Vogel, MD, on the final overall survival data for camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.
ASCO has updated its recommendations for abemaciclib and ribociclib as adjuvant treatment for breast cancer.
Suresh S. Ramalingam, MD, FACP, FASCO, discusses findings with osimertinib after definitive chemoradiotherapy in unresectable EGFR-mutated NSCLC.
The OncoAlert Newsletter is now out for June 23-29, 2023
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
PET-guided BrECADD should be a standard treatment option for patients with advanced-stage classic Hodgkin lymphoma, according to researchers.
Ahmad A. Tarhini Departments of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL Ahmad A. Tarhini, Tingyi Li, Sandra…
An abstract is unavailable.
Kamran A. Ahmed H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL Kamran A. Ahmed, Youngchul Kim, Michelle DeJesus, Daniel Eli Oliver, Matthew Mills,…